TOKYO: Japan on Thursday (Dec 16) officially approved Moderna's COVID-19 vaccine for its booster shot programme, while Novavax filed for first approval of its shot in the country.
Moderna's mRNA-type vaccine, used mostly in Japan to date at workplace inoculation sites, was approved for used as a third booster shot for those aged 18 or older, following a recommendation from health ministry experts on Wednesday.
That is the same age range applied to the shot developed by Pfizer and BioNTech, which has been given out about 93,000 times as a booster through Wednesday, taking in about 0.1 per cent of the population.
Novavax's protein-based vaccine was submitted to regulators by its Japanese distributor Takeda Pharmaceutical, the company said in a statement. Pending approval, Takeda plans to make the vaccine in Japan and distribute it in early 2022.
After a relatively late start, Japan has fully inoculated almost 80 per cent of its population, the highest among Group of Seven economies. The country has about 31 million doses left between the Pfizer and Moderna shots, with deals in place to get 170 million more in 2022.
https://news.google.com/__i/rss/rd/articles/CBMiWmh0dHBzOi8vd3d3LmNoYW5uZWxuZXdzYXNpYS5jb20vYXNpYS9jb3ZpZC0xOS12YWNjaW5lLWJvb3N0ZXItbW9kZXJuYS1wZml6ZXItamFwYW4tMjM4MzMxMdIBAA?oc=5
2021-12-16 03:34:00Z
1190711005
Tidak ada komentar:
Posting Komentar